Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has been assigned a $15.00 price target by research analysts at Roth Capital in a report released on Sunday. The brokerage presently has a “buy” rating on the stock. Roth Capital’s target price suggests a potential upside of 70.07% from the company’s current price.

Several other research analysts have also issued reports on the company. Zacks Investment Research raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. ValuEngine raised Zynerba Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price target on shares of Zynerba Pharmaceuticals in a report on Tuesday, August 8th. CIBC restated a “market perform” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, August 15th. Finally, Piper Jaffray Companies raised shares of Zynerba Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $7.00 to $16.00 in a research note on Thursday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $15.78.

Shares of Zynerba Pharmaceuticals (NASDAQ ZYNE) traded up 6.10% during midday trading on Friday, hitting $8.87. 1,510,802 shares of the stock traded hands. The firm’s 50-day moving average is $6.28 and its 200 day moving average is $6.28. The company’s market capitalization is $117.59 million. Zynerba Pharmaceuticals has a 52 week low of $6.10 and a 52 week high of $23.57.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Tuesday, August 1st. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Equities analysts forecast that Zynerba Pharmaceuticals will post ($2.42) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Zynerba Pharmaceuticals, Inc. (ZYNE) Given a $15.00 Price Target by Roth Capital Analysts” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.watchlistnews.com/zynerba-pharmaceuticals-inc-zyne-given-a-15-00-price-target-by-roth-capital-analysts/1603726.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZYNE. Nationwide Fund Advisors acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter worth approximately $110,000. The Manufacturers Life Insurance Company acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at about $158,000. FNY Managed Accounts LLC bought a new stake in shares of Zynerba Pharmaceuticals during the first quarter worth about $180,000. SG Americas Securities LLC bought a new stake in shares of Zynerba Pharmaceuticals during the first quarter worth about $188,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth about $207,000. Hedge funds and other institutional investors own 34.32% of the company’s stock.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.